Medicare Enrolled
Dr. Tri Le, M.D.
Hematology & Oncology · Bedford, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Le from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Le? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Le
Dr. Tri Le is a hematology & oncology in Bedford, TX, with 11 years in practice. Based on federal Medicare data, Dr. Le performed 49,820 Medicare services across 2,814 unique beneficiaries.
Between the years covered by Open Payments, Dr. Le received a total of $1,968 from 21 pharmaceutical and/or device companies across 49 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Payments are distributed across multiple categories and often reflect legitimate professional engagement with the medical industry. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Le is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice▲ Top 19% volume in TX$ $1,968 industry payments
Medicare Practice Summary
Medicare Utilization ↗49,820
Medicare services
Top 19% in TX for hematology & oncology
2,814
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,529 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 11,220 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 9,200 | $43 | $137 |
| Contrast dye for imaging (iodine-based) | 6,870 | $0 | $3 |
| Iron sucrose injection (Venofer) | 5,400 | $0 | $2 |
| Paclitaxel chemotherapy injection | 5,382 | $0 | $8 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,289 | $20 | $181 |
| Dexamethasone injection (steroid) | 1,366 | $0 | $1 |
| Complete blood count (CBC) with differential | 740 | $8 | $36 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 636 | $79 | $1,348 |
| Comprehensive metabolic blood panel | 604 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 540 | $0 | $24 |
| Blood draw (venipuncture) | 489 | $8 | $20 |
| Cyclophosphamide, 100 mg | 398 | $15 | $203 |
| Administration of chemotherapy into vein, 1 hour or less | 300 | $101 | $707 |
| Office visit, established patient (30-39 min) | 287 | $91 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 284 | $23 | $157 |
| Lactate dehydrogenase (enzyme) level | 265 | $6 | $31 |
| Injection, doxorubicin hydrochloride, 10 mg | 259 | $2 | $54 |
| Iron level test | 224 | $6 | $27 |
| Iron binding capacity test | 224 | $9 | $35 |
| Office visit, established patient, complex (40-54 min) | 218 | $137 | $496 |
| Ferritin level test (iron stores) | 217 | $13 | $60 |
| Injection, carboplatin, 50 mg | 172 | $2 | $300 |
| Anti-nausea injection (Aloxi/palonosetron) | 170 | $1 | $114 |
| Office visit, established patient (20-29 min) | 158 | $59 | $250 |
| Injection, diphenhydramine hcl, up to 50 mg | 117 | $1 | $7 |
| Administration of chemotherapy into vein, each additional hour | 105 | $22 | $161 |
| Drug injection, under skin or into muscle | 100 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 98 | $49 | $313 |
| Administration of additional new drug or substance into vein, 1 hour or less | 82 | $50 | $344 |
| Ct scan of chest with contrast | 75 | $37 | $821 |
| Reticulated (young) platelet measurement | 73 | $35 | $143 |
| Injection, zoledronic acid, 1 mg | 64 | $6 | $431 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $50 | $211 |
| CT scan of abdomen and pelvis with contrast | 62 | $140 | $1,067 |
| Carcinoembryonic antigen (cea) protein level | 60 | $19 | $99 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 60 | $91 | $657 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 54 | $330 | $1,722 |
| Unclassified drugs | 53 | $1 | $8 |
| Application of on-body injector for under skin injection | 51 | $15 | $96 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 50 | $1,166 | $4,802 |
| Administration of additional new drug or substance into vein using push technique | 49 | $43 | $289 |
| Red blood count automated, with additional calculations | 47 | $5 | $26 |
| New patient office visit, complex (60-74 min) | 44 | $160 | $709 |
| Basic metabolic blood panel | 42 | $8 | $49 |
| Infusion, normal saline solution , 1000 cc | 41 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 39 | $16 | $100 |
| Hospital follow-up visit, low complexity | 39 | $39 | $135 |
| Magnesium level test | 37 | $7 | $29 |
| Phosphate level test | 36 | $5 | $24 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 35 | $286 | $2,762 |
| Hospital follow-up visit, moderate complexity | 34 | $62 | $247 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $24 | $145 |
| Hospital follow-up visit, high complexity | 32 | $93 | $357 |
| New patient office visit (45-59 min) | 29 | $119 | $565 |
| Microscopic examination for white blood cells with manual cell count | 28 | $4 | $22 |
| Complete blood count (CBC), automated | 28 | $6 | $34 |
| Irrigation of implanted venous access drug delivery device | 25 | $18 | $114 |
| Initial hospital admission, high complexity | 21 | $136 | $694 |
| Injection of additional new drug or substance into vein | 20 | $12 | $108 |
| Initial hospital admission, moderate complexity | 20 | $102 | $470 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $23 | $256 |
| Infusion into a vein for hydration, each additional hour | 17 | $10 | $75 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 15 | $4 | $33 |
| Nuclear medicine study whole body with ct scan | 11 | $1,169 | $4,929 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.5% high complexity
67.0% medium
9.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,968
Total received (2019-2024)
Avg $492/year across 4 years
Bottom 40% in TX for hematology & oncology
21
Companies
49
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Other
Charitable contributions, space rental, and other categories
$1,047 (53.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$702 (35.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$219 (11.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,387
2023$358
2022$124
2019$99
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,047
Gilead Sciences, Inc.
$121
Incyte Corporation
$120
Alexion Pharmaceuticals, Inc.
$99
Celgene Corporation
$85
Merck Sharp & Dohme LLC
$61
ABBVIE INC.
$53
Eisai Inc.
$48
E.R. Squibb & Sons, L.L.C.
$45
GENZYME CORPORATION
$44
GlaxoSmithKline, LLC.
$37
Adaptive Biotechnologies Corporation
$34
Pharmacyclics LLC, An AbbVie Company
$27
Regeneron Healthcare Solutions, Inc.
$24
AstraZeneca Pharmaceuticals LP
$24
ADC Therapeutics America, Inc.
$19
Janssen Biotech, Inc.
$18
Lilly USA, LLC
$18
Takeda Pharmaceuticals U.S.A., Inc.
$16
PFIZER INC.
$15
Bayer Healthcare Pharmaceuticals Inc.
$14
Top 3 companies account for 65.4% of total payments
Associated products mentioned in payments ›
AREXVY · CABLIVI · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · ICLUSIG · INLYTA · JAKAFI · JAYPIRCA · JEMPERLI · KEYTRUDA · KISQALI · LIBTAYO · Lenvima · Nubeqa · OPDIVO · PLUVICTO · Pomalyst · REBLOZYL · SOLIRIS · Trodelvy · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Payments are distributed across multiple categories with no single dominant type.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
144
Per 100K population
6.7
County median income
$81,905
Nearest hospital
TEXAS HEALTH HARRIS METHODIST HURST-EULESS-BEDFORD
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Le is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), and mixed engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Le experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Le performed 11,220 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Le receive payments from pharmaceutical companies?
Yes. Dr. Le received a total of $1,968 from 21 companies across 49 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Le's costs compare to other hematology & oncologys in Bedford?
Dr. Le's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Le) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Bedford
Browse hematology & oncologys in Bedford ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc..
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology